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One‑year urinary and sexual outcome
trajectories among prostate cancer patients
treated by radical prostatectomy: a prospective
study
Lin Yang1,2,3* , Jung Ae Lee4, Emily Heer1, Claire Pernar5, Graham A. Colditz3, Ratna Pakpahan3, Kellie R. Imm3,10,
Eric H. Kim, Robert L. Grubb III6,7, Kathleen Y. Wolin8, Adam S. Kibel9 and Siobhan Sutcliffe3

Abstract
Background: To examine one-year trajectories of urinary and sexual outcomes, and correlates of these trajectories,
among prostate cancer patients treated by radical prostatectomy (RP).
Methods: Study participants were recruited from 2011 to 2014 at two US institutions. Self-reported urinary and
sexual outcomes were measured at baseline before surgery, and 5 weeks, 6 months and 12 months after surgery,
using the modified Expanded Prostate Cancer Index Composite-50 (EPIC-50). Changes in EPIC-50 scores from baseline
were categorized as improved (beyond baseline), maintained, or impaired (below baseline), using previously-reported
minimum clinically important differences.
Results: Of the 426 eligible participants who completed the baseline survey, 395 provided data on at least one
EPIC-50 sub-scale at 5 weeks and 12 months, and were analyzed. Although all mean EPIC-50 scores declined markedly 5 weeks after surgery and then recovered to near (incontinence-related outcomes) or below (sexual outcomes)
baseline levels by 12 months post-surgery, some men experienced improvement beyond their baseline levels on
each sub-scale (3.3–51% depending on the sub-scale). Having benign prostatic hyperplasia (BPH) at baseline (prostate
size ≥ 40 g; an International Prostate Symptom Index Score ≥ 8; or using BPH medications) was associated with postsurgical improvements in voiding dysfunction-related bother at 5 weeks (OR = 3.9, 95% CI: 2.1–7.2) and 12 months
(OR = 3.3, 95% CI: 2.0–5.7); and in sexual bother at 5 weeks (OR = 5.7, 95% CI:1.7–19.3) and 12 months (OR = 3.0, 95%
CI: 1.2–7.1).
Conclusions: Our findings provide additional support for considering baseline BPH symptoms when selecting the
best therapy for early-stage prostate cancer.
Keywords: Localized prostate cancer, Benign prostatic hyperplasia, Radical prostatectomy, Urinary outcome, Sexual
outcome
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Background
Early-stage, localized prostate cancer can be managed in
several ways, including watchful waiting, active surveillance, and curative modalities such as radical prostatectomy (RP), external radiotherapy, and brachytherapy. As
each of these modalities has high survival rates [1], the
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benefits of curative therapies must be carefully weighed
against their harms, including their side effects [2–4].
A number of studies have documented the natural history of prostate cancer treatment side effects [5–12]. For
RP, in particular, studies indicate that men tend to experience an initial large decline in urinary and sexual function immediately after surgery (i.e., within the first two
months), followed by a gradual improvement to near
or below baseline levels by the first year post-surgery.
One exception to this pattern is voiding dysfunction (or
urinary irritation or obstruction). Symptoms of voiding dysfunction have been observed to improve beyond
pre-surgical values in a few previous studies, presumably
because of relief of urinary obstruction by prostatectomy
in men with both prostate cancer and benign prostatic
hyperplasia (BPH) [13]. These findings have led AUA,
ASTRO, and SUO to recommend surgery over radiation
therapy for patients with clinically localized prostate cancer and obstructive, non-cancer-related lower urinary
tract dysfunction [14]. However, as this recommendation
is Grade C, additional high-quality evidence from randomized controlled trials and prospective observational
studies is still needed.
To our knowledge, voiding dysfunction is the only outcome in which improvement beyond pre-surgical values
has been explored. Although mean improvement has not
been observed in other outcomes, such as sexual function
or bother, it is possible that examination of mean trajectories may have obscured improvement or other trajectories experienced by only a subset of participants—for
instance, those who use medication and devices to treat
their erectile dysfunction (ED) after surgery. Understanding the full range of side effect trajectories would be useful to help set patients’ expectations post-surgery and to
further aid with treatment decision-making. Therefore,
we analyzed data from the prospective Prostatectomy,
Incontinence, and Erectile Dysfunction (PIE) Study to
describe the full range of urinary and sexual side effect
trajectories, the percentage of patients with improvement
beyond baseline in each domain, and factors related to
improvement in the first year post-surgery (i.e. BPH- and
ED-related factors).

Methods
Study population and design

Prostate cancer patients were recruited into the PIE study
from 2011 to 2014 at two sites, Washington University
School of Medicine and Brigham & Women’s Hospital.
All men undergoing RP for clinically localized prostate
cancer were eligible, except for those who: (1) had previously undergone treatment for prostate cancer, radiation
therapy to the pelvis (including bladder, rectum, or prostate), or major pelvic surgery (including penile implant
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or urinary sphincter); (2) had known urethral stricture
or colostomy; (3) were unable to urinate and required
indwelling catheterization; and (4) did not speak English.
Men who received neo-adjuvant therapy or any additional prostate cancer-related therapies (e.g., radiation or
hormonal therapies) during the one-year study followup were excluded from the analyses. The PIE study was
approved by the institutional review boards at both institutions. All participants provided informed consent.
Urinary and sexual outcomes

Patient-reported urinary and sexual outcomes were
assessed at baseline before RP, and 5 weeks, 6 months,
and 12 months post-RP by the modified Expanded Prostate Cancer Index Composite-50 (EPIC-50) [15]. This
validated scale includes sub-scales for urinary function
(i.e., continence), urinary bother, sexual function, and
sexual bother. We split the urinary bother scale into two
sub-scales to distinguish incontinence-related bother
from voiding dysfunction-related bother [16]. For each
EPIC-50 sub-scale, a summary score was calculated and
then transformed linearly to a 0-to-100 scale, with higher
scores indicating better function and less bother.
Demographic and lifestyle factors

Before RP, participants completed a baseline questionnaire including items on age, education, household
income, race/ethnicity, insurance status, and marital status, as well as lifestyle factors, such as cigarette smoking
history. Self-reported data on frequency of performing
pelvic floor (i.e., Kegel) exercises after RP was ascertained
on the follow-up questionnaires.
BPH‑ and ED‑related factors

We abstracted data on clinical characteristics from participants’ medical charts. These included comorbidities
(Charlson Comorbidity Index), prostate cancer characteristics (pre-surgical clinical staging, prostate-specific
antigen [PSA] concentration, and post-surgical pathological staging); pre-surgical urological conditions, including BPH (prostate size measured from the RP specimen,
International Prostate Symptom Index [IPSS], and selfreported BPH medication use [overall, α-blocker use
only, and 5α-reductase inhibitor use with or without
α-blockers]); surgical characteristics taken from the operative note (blood loss during surgery, attempted number of neurovascular bundles preserved, type of surgical
procedure, and bladder neck reconstruction), and sexual
dysfunction therapies (pre- and post-surgical ED medication and device use).
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Statistical analysis

To begin to explore and display the distributions of urinary and sexual outcomes over time, we constructed boxplots with lines connecting the mean values from baseline
through 12 months. This display is similar to figures presented in previous analyses of post-RP outcomes. Next,
we investigated side effect trajectories by calculating the
difference in each urinary and sexual outcome between
baseline and 12 months for each participant and then
by ranking participants according to their magnitude of
change for each outcome (i.e., from the minimum to the
maximum). To illustrate these trajectories, we selected a
sample of participants (i.e., those ranked at the 5th, 25th,
50th, 75th, and 95th percentiles) for each outcome and
plotted each participant’s change from baseline through
12 months, analogous to a selective “spaghetti plot”.
Given that some changes may be too small to be
meaningful to patients, we next categorized both shortand long-term changes (from baseline to 5 weeks and
12 months, respectively) into clinically meaningful categories, using sub-scale-specific minimum clinically
important difference (MCID) ranges reported by Skolarus and colleagues [17]. The upper bounds of these subscale-specific ranges were chosen to obtain conservative
estimates: i.e., 9 point change in the urinary domain (7
for voiding dysfunction-related symptoms) and 12-point
change in the sexual domain [17]. We used these subscale-specific values to create the following categories
of change: improved beyond baseline (positive change
greater than the MCID), maintained (within the positive to negative values of the MCID), and impaired below
baseline (negative change greater than the MCID) [16,
18]. We also used the lower bounds of sub-scale-specific
ranges to classify participants in sensitivity analyses.
Multinomial logistic regression was used to explore
BPH- and ED-related factors associated with short- and
long-term improvement beyond baseline and maintenance in urinary and sexual outcomes (in sub-scales with
at least 10 men for stable estimation). Factors considered
were individual measures of BPH (pre-surgical prostate
size, IPSS score, and reported use of BPH medications,
overall and separately by type), as well as a composite
BPH outcome (prostate size ≥ 40 g [19], IPSS score ≥ 8
[20], or medication use), and measures of sexual dysfunction (pre- and post- surgical ED medication and device
use). Sensitivity analyses were performed by: (1) adjusting for factors significantly associated with improvement
or maintenance in at least one urinary or sexual outcome;
(2) using the lower bounds of the EPIC-50 sub-scale-specific MCID ranges to classify participants; (3) excluding
men with pre-surgical EPIC-50 scores too high to experience improvement (i.e., higher than the value obtained
by subtracting the sub-scale specific MCID from 100); (4)
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restricting to men with complete data on specific urinary
and sexual outcomes at baseline, 5 weeks and 12 months;
and (5) repeating the analyses using the 6 month followup data.

Results
Participant characteristics

Of the 426 eligible participants who completed the baseline survey, 395 (92.7%) provided data on at least one
EPIC-50 sub-scale at baseline, 5 weeks, or 12 months,
and were included in the analysis. The majority of
included participants (mean age = 60.7 years) were Caucasian (91.9%), had completed at least some college education (83.6%), earned ≥ $75,000 per year (61.4%), were
married or living with a partner (82.5%), and had never
smoked (62.5%, Table 1). Among participants with data
on the Charlson Comorbidity Index (n = 167), 103 (61.7%
of 103 and 26.2% of 394) had at least one comorbidity.
Considering their prostate cancer-specific characteristics, most participants had clinical stage T1 (78.5%) and
pathologic stage T3 (88.9%) disease, with a pre-surgical
PSA concentration between 4 and 10 ng/mL. The majority (92.3%) of men underwent a minimally-invasive RP
and 65.2% had a bilateral never-sparing procedure.
Changes in urinary and sexual outcomes

With respect to urinary incontinence, most men had high
function (mean = 93.1) and bother scores (mean = 95.8,
i.e., good function and not much bother) at baseline.
Scores for voiding dysfunction-related bother were also
high (mean = 74.5), but lower than for incontinencerelated bother. With respect to sexual outcomes, baseline levels were lower than for urinary outcomes, and
were also lower for sexual function (mean = 56.2) than
for bother (mean = 68.9), indicating worse sexual function but not as much bother (Fig. 1a–e). Five weeks after
surgery, mean levels of each of these outcomes were
markedly decreased. For urinary incontinence-related
outcomes, levels recovered to near, but below, baseline
6 months post-surgery and then slowed to a plateau by
12 months. In contrast, for voiding dysfunction-related
bother, levels recovered to above baseline 6 months postsurgery and then remained relatively constant through
12 months. Finally, for sexual-related outcomes, mean
levels remained well below baseline but continued to
improve gradually through 12 months post-surgery.
When individual trajectories of change were examined, a generally similar impression of symptom change
was obtained, particularly when viewing the median
(50th) percentile trajectories (Fig. 2a–e). However, these
displays also highlighted improved (beyond baseline) or
maintained outcomes in all domains over time. Improvement was greatest for voiding dysfunction-related bother
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Table 1 Socio-demographic, lifestyle, and clinical characteristics
of prostate cancer patients in the prostatectomy, incontinence
and erectile dysfunction (PIE) study
N

Age (years, mean, SD)

395

60.7 (6.9)

Caucasian (%)

385

91.9

Education (%)

385

High school degree or less

16.4

Some college

30.9

College degree

23.9

Household income (%)

28.8
18.3

$50,000—< $75,000

20.3
61.4

Married or living with a partner (%)

395

Smoking (%)

385

82.5

Never smoker

62.5

Former smoker

32.7

Current smoker
Charlson Comorbidity Index (%)

6.8
394

No comorbidities

16.2

Any comorbidities

26.2

Missing

57.6

Prostate cancer- and surgery-related factors
Clinical T1 stage (%)

381

Pathological stage (%)

389

T2

78.5
11.1

T3

88.9

Pre-surgical prostate-specific antigen concentration (ng/mL, mean, SD)

393

6.3 (4.6)

Blood loss during surgery (mL, mean, SD)

358

246.3 (203.3)

Neurovascular bundle preservation (%)

351

Non-nerve sparing

19.4

Unilateral neurovascular bundle spared

15.4

Bilateral nerve sparing
Surgical procedure (%)

65.2
365

Minimally-invasive (robotic and laparoscopic)

92.3

Open
Bladder reconstruction

(22.1% of men at 5 weeks; 50.9% at 12 months), followed
by sexual bother (7.3% at 5 weeks; 10.6% at 12 months),
and urinary function (9.8% at 12 months, Tables 2 and 3).
Lesser proportions of men experienced improvement in
incontinence-related bother and sexual function (< 5%).
Of note, improvement beyond baseline was observed
even as early as 5 weeks post-surgery, particularly for
voiding dysfunction-related and sexual bother.

365

< $50,000
≥ $75,000

BPH benign prostatic hyperplasia, ED erectile dysfunction, IPSS International
Prostate Symptom Score, SD standard deviation

% or mean (SD)

Socio-demographic and lifestyle factors

Post graduate

Table 1 (continued)

7.7
364

53.0

Prostate size (grams, mean, SD)

288

43.5 (16.6)

IPSS score at baseline (mean, SD)

249

8.6 (6.7)

BPH medication use at baseline (%)

395

BPH-related factors

13.2

α-blocker use

10.4

5α-reductase inhibitor (and α-blocker) use

2.8

Urinary and sexual function-related factors
Reported Kegel exercises
5 weeks post-surgery

358

67.3

12 months post-surgery

332

31.3

ED medication or device use (%)
Baseline

365

4.8

5 weeks post-surgery

365

30.1

12 months post-surgery

336

18.2

Factors associated with improvement beyond baseline
in urinary and sexual outcomes

No significant associations were observed for BPH- or
ED-related factors with improved or maintained urinary
function or incontinence-related bother after surgery
(only evaluable at 12 months, Table 2 and Additional
file 1: Table 1). In contrast, each of the individual measures of BPH, as well as the BPH composite measure, were
associated with improved voiding dysfunction-related
bother at both 5 weeks and 12 months post-surgery
(5 weeks: odds ratio [OR] = 3.9, 95% confidence interval [CI]: 2.1–7.2; 12 months: OR = 3.3, 95% CI: 2.0–5.7
for the BPH composite measure). No associations were
observed for ED medication or device use at baseline or
follow-up.
With respect to sexual outcomes, no significant associations were observed for BPH- or ED-related factors
with improved or maintained sexual function. In contrast, the BPH composite measure was associated with
improved sexual bother at both 5 weeks (OR = 5.7, 95%
CI:1.7–19.3) and 12 months post-surgery (OR = 3.0, 95%
CI: 1.2–7.1, Table 3 and Additional file 1: Table 2). Positive associations were also observed for several of the
individual measures of BPH, including α-blocker use
(OR = 4.4, 95% CI: 1.1–18.0) with improvement in sexual
function at 12 months post-surgery, and BPH medication use (OR = 5.4, 95% CI: 2.2–13.0) and α-blocker use
(OR = 5.6, 95% CI: 2.2–14.6) with improvement in sexual
bother at 5 weeks. Finally, an inverse association was
observed for ED medication or device use during followup with maintained sexual function (OR = 0.5, 95% CI:
0.3–0.9) and bother (OR = 0.5, 95% CI: 0.3–1.0) compared to impaired function and bother 12 months postsurgery. This is likely due to confounding by indication,
whereby men who experienced large declines in sexual
function may have been more likely to use ED medications or devices after surgery.
Similar results were observed in sensitivity analyses: (1)
adjusting for age, smoking status, living arrangement, and
neurovascular bundle preservation; (2) using the lower
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Fig. 1 Changes in Urinary and Sexual Outcomes (mean values) Assessed by the Expanded Prostate Cancer Index Composite (EPIC)-50 among Men
in the Prostatectomy, Incontinence and Erectile Function (PIE) Study, between Baseline and 12 Months Post-Radical Prostatectomy

bounds of the EPIC-50 sub-scale-specific MCID ranges;
(3) excluding men with high pre-surgical scores in each
EPIC-50 sub-scale; (4) restricting to men with complete
outcome data at baseline, 5 weeks and 12 months; and
(5) examining the 6-month follow-up data (results not
shown).

Discussion
Similar to previous studies, our study demonstrated sharp
declines in mean urinary and sexual outcomes 5 weeks
post-RP, followed by recovery to near, but below, baseline
values for urinary incontinence-related outcomes, and

to improved, but well below, baseline values for sexual
outcomes. However, by examining individual participant
trajectories, we also identified several groups of men who
experienced improvement beyond their baseline values
in each urinary and sexual outcome. Notably, a considerable proportion of men experienced immediate and
long-term improvement in voiding dysfunction-related
bother, and a small proportion experienced long-term
improvement in urinary function (continence) and sexual
bother. To our knowledge, improvement in outcomes
besides voiding dysfunction has not previously been documented. Additionally, we found that pre-surgical BPH
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Fig. 2 Individual Trajectories of Urinary and Sexual Outcomes Assessed by the Expanded Prostate Cancer Index Composite (EPIC)-50 among Men
in the Prostatectomy, Incontinence and Erectile Function (PIE) Study from Baseline through 12 Months Post-Radical Prostatectomy (The trajectories
for five different individuals per domain are presented in each graph. These individuals were selected by subtracting each participant’s 12 month
follow-up values in each EPIC-50 domain from their baseline values and then by ranking these differences. The outcome trajectories for participants
ranked at the 5th, 25th, 50th, 75th, and 9 5th percentiles of change for each domain are presented to illustrate the range of trajectories experienced by
participants. In each domain, participants at the 95th percentile experienced improvement)

was associated with improvement beyond baseline in
both voiding dysfunction and sexual bother, strengthening the evidence in national urologic oncology guidelines
to recommend surgical treatment for appropriate prostate cancer patients with BPH.
Our finding of clinically meaningful improvement in
urinary continence among a small proportion of men
treated for prostate cancer by RP was unexpected and
differs from most previously published findings [10, 21,
22]. One possible explanation for this finding may be
surgical elimination of bladder outlet resistance by RP.

Studies of bladder outlet resistance have demonstrated
that the bladder detrusor muscle undergoes structural
and functional changes, with initial hypertrophy, then
compensation, and then decompensation [23–25]. The
bladders of men with BPH who undergo RP for prostate cancer may lie anywhere along this spectrum. Men
in an initial hypertrophic stage may have some degree of
urge-related urinary incontinence, which may be relieved
by bladder remodelling following surgical elimination of
outlet resistance by RP. Likewise, men in a late decompensated stage may have some degree of stress-related

< 40 g

3 (0.8)

28 (7.4)

346 (91.8)

34 (9.8)

168 (48.4)

145 (41.8)

1.7 (0.6 to 4.0)

11

1.5 (0.9 to 2.6)

52

Reference

57

OR 95% CI

N

3 (0.8)

110 (29.0)

266 (70.3)

17

71

51

2.1 (0.7 to 6.2)

6

1.0 (0.6 to 1.7)

58

Reference

11

51

46

≥8

1.7 (0.6 to 4.8)

28

1.1 (0.5 to 2.2)

148

Reference

129

No

6

20

16

Yes

1.6 (0.7 to 3.5)

11

1.2 (0.8 to 2.0)

64

Reference

63

No BPH

23

104

82

Any
BPH

1.7 (0.4 to 6.6)

31

0.5 (0.2 to 1.6)

163

Reference

137

No

3

5

8

Yes

0.7 (0.3 to 1.5)

13

0.8 (0.5 to 1.4)

59

Reference

46

No

ED medication
or device use at
follow-up

18

102

94

Yes

(2021) 21:81

Improved

OR 95% CI

N

Maintained

OR 95% CI

N

Impaired

Incontinence-related bother 5 weeks post-surgery (n = 379)

OR 95% CI

N

Improved

OR 95% CI

N

Maintained

OR 95% CI

N

Impaired

Urinary function (continence) 12 months post-surgery (n = 347)

OR 95% CI

N

Improved

OR 95% CI

N

Maintained

OR 95% CI

N

Impaired

53

≥ 40 g < 8

BPH composite
measure

ED medication use at
baseline

BPH medication use at
baseline

Prostate size

IPSS score

ED-related factors

BPH-related factors

Urinary function (continence) 5 weeks post-surgery (n = 377)

All participants n (%)

Table 2 Factors Associated with urinary outcome trajectories assessed by the expanded prostate cancer index composite (EPIC)-50 among men in the prostatectomy,
incontinence and erectile dysfunction (PIE) study
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< 40 g

13 (3.7)

282 (81.0)

53 (15.2)

1.0 (0.3 to 3.8)

5

0.8 (0.4 to 1.5)

103

Reference

16

7

109

22

84 (22.1)

58 (15.3)

238 (62.6)

2.1 (1.2 to 3.9)

20

0.9 (0.4 to 1.8)

21

Reference

93

41

18

89

5.5 (2.8 to 11.0)

14

1.1 (0.5 to 2.3)

23

Reference

91

N

177 (50.9)

80 (23.0)

91 (26.1)

49

0.8 (0.4 to 1.7)

37

Reference

38

80

26

32

47

0.7 (0.3 to 1.5)

35

Reference

36

74

13

20

46

15

54

6

87

14

148

0.8 (0.2 to 2.6)

75

Reference

84

2.7 (1.4 to 5.2)

63

0.6 (0.2 to 1.8)

54

Reference

212

3.5 (0.8 to 15)

9

1 (0.4 to 2.4)

251

Reference

47

No

29

5

7

21

4

26

4

31

6

Yes

46

1.0 (0.5 to 1.7)

44

Reference

49

3.9 (2.1 to 7.2)

15

1.0 (0.5 to 1.7)

27

Reference

109

2.6 (0.6 to 10.4)

3

1.1 (0.6 to 2.1)

113

Reference

23

No BPH

Any
BPH

131

36

42

69

31

129

10

169

30

169

1.1 (0.3 to 4.7)

76

Reference

87

0.9 (0.3 to 3.0)

80

1.0 (0.3 to 3.8)

55

Reference

226

NE

13

0.8 (0.2 to 2.9)

269

Reference

50

No

8

4

4

4

3

12

0

13

3

Yes

67

1.4 (0.7 to 2.6)

22

Reference

32

1.3 (0.8 to 2.2)

38

1.9 (1.0 to 3.5)

22

Reference

126

0.5 (0.2 to 1.9)

6

1.0 (0.5 to 1.8)

97

Reference

18

No

ED medication
or device use at
follow-up

103

53

57

40

33

99

6

174

33

Yes

(2021) 21:81

Improved

OR 95% CI

N

Maintained

OR 95% CI

N

Impaired

Voiding dysfunction-related bother 12 months post-surgery (n = 348)

OR 95% CI

N

Improved

OR 95% CI

N

Maintained

OR 95% CI

N

Impaired

5.4 (1.0 to 30.2)

2

1.7 (0.8 to 3.5)

91

Reference

25

≥ 40 g < 8

Voiding dysfunction-related bother 5 weeks post-surgery (n = 380)

OR 95% CI

N

Improved

OR 95% CI

N

Maintained

OR 95% CI

N

Impaired

≥8

BPH composite
measure

ED medication use at
baseline

BPH medication use at
baseline

Prostate size

IPSS score

ED-related factors

BPH-related factors

Incontinence-related bother 12 months post-surgery (n = 348)

All participants n (%)

Table 2 (continued)
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≥8

BPH composite
measure

1.9 (1.1 to 3.5)

< 40 g
2.8 (1.5 to 5.5)

≥ 40 g < 8
2.4 (1.0 to 5.6)

No

Yes

3.3 (2.0 to 5.7)

No BPH

Any
BPH

Yes

0.9 (0.5 to 1.5)

No

ED medication
or device use at
follow-up
Yes

EPIC-50 measured urinary and sexual outcome trajectories were defined as impaired (negative change greater than the upper bound of minimally important difference), maintained, and improved (positive change
greater than the upper bound of minimally important difference). Urinary function, incontinence-related bother: impaired (change < 9); maintained (− 9 ≤ change ≤ 9); improved (change ≥ 9). Voiding dysfunction-related
bother: impaired (change < 7); maintained (− 7 ≤ change ≤ 7); improved (change ≥ 7)

1.0 (0.3 to 3.5)

No

ED medication use at
baseline

BPH medication use at
baseline

Prostate size

IPSS score

ED-related factors

BPH-related factors

BPH benign prostatic hyperplasia, CI confidence interval, ED erectile dysfunction, IPSS International Prostate Symptom Score, OR odds ratio, NE not estimable

OR 95% CI

All participants n (%)

Table 2 (continued)
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6 (1.7)

69 (19.3)

262 (79.0)

11 (3.3)

92 (27.7)

229 (69.0)

76

1.6 (0.4 to 6.5)

3

0.6 (0.3 to 1.0)

39

Reference

N

OR 95% CI

26 (7.3)

69 (19.5)

259 (73.2)

94

1.8 (0.6 to 5.1)

6

1.0 (0.5 to 1.8)

27

Reference

11

27

96

6

28

96

73

1.5 (0.6 to 4.0)

8

0.9 (0.5 to 1.7)

27

Reference

86

1.0 (0.2 to 4.2)

4

0.8 (0.4 to 1.4)

35

Reference

11

22

77

4

28

73

5.4 (2.2 to 13.0)

16

1.1 (0.5 to 2.6)

61

Reference

232

3.2 (0.8 to 13)

8

1.3 (0.6 to 2.7)

80

Reference

205

No

10

8

27

3

12

24

Yes

5.7 (1.7 to 19.3)

3

1.0 (0.6 to 1.6)

30

Reference

110

3.0 (0.6 to 14)

2

0.8 (0.5 to 1.4)

40

Reference

91

No BPH

23

39

149

9

52

138

Any BPH

1.3 (0.3 to 5.8)

24

NE

69

Reference

243

NE

11

0.8 (0.3 to 2.6)

88

Reference

217

No

2

0

16

0

4

12

Yes

0.6 (0.2 to 1.3)

16

0.6 (0.3 to 1.1)

36

Reference

117

1.1 (0.2 to 6.0)

2

0.5 (0.3 to 0.9)

40

Reference

70

No

ED medication
or device use at
follow-up

10

24

131

5

48

154

Yes

(2021) 21:81

Improved

OR 95% CI

N

Maintained

OR 95% CI

N

Impaired

Sexual bother 5 weeks post-surgery (n = 354)

OR 95% CI

N

Improved

OR 95% CI

N

Maintained

OR 95% CI

N

Impaired

Sexual function 12 months post-surgery (n = 332)

OR 95% CI

N

Improved

OR 95% CI

N

Maintained

OR 95% CI

N

Impaired

≥8

<8

< 40 g

≥ 40 g

ED medication
use at baseline ED
medication use at
baseline

IPSS score

Prostate size

BPH medication use at BPH composite measure
baseline

ED -elated factors

BPH-related factors

Sexual function 5 weeks post-surgery (n = 357)

All participants n (%)

Table 3 Factors associated with sexual outcome trajectories assessed by the expanded prostate cancer index composite (EPIC)-50 among men in the prostatectomy,
incontinence and erectile dysfunction (PIE) study
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35 (10.6)

65 (19.8)

229 (69.6)

78

2.1 (0.9 to 5.0)

8

0.7 (0.4 to 1.4)

28

Reference

19

23

89

81

1.6 (0.7 to 3.8)

11

1.0 (0.5 to 2.1)

22

Reference

15

19

67

1.5 (0.5 to 4.2)

30

1.4 (0.6 to 3.3)

56

Reference

206

No

5

9

23

Yes

3.0 (1.2 to 7.1)

7

1.0 (0.6 to 1.7)

28

Reference

98

No BPH

28

37

131

Any BPH

NE

35

0.8 (0.2 to 2.9)

62

Reference

216

No

0

3

13

Yes

0.5 (0.2 to 1.2)

13

0.5 (0.3 to 1.0)

27

Reference

68

No

ED medication
or device use at
follow-up

EPIC-50 measured urinary and sexual outcome trajectories were defined as impaired (negative change greater than the upper bound of minimally important difference), maintained, and improved (positive change
greater than the upper bound of minimally important difference). Sexual function, sexual bother: impaired (change < 12); maintained (-12 ≤ change ≤ 12); improved (change ≥ 12)

BPH benign prostatic hyperplasia, CI confidence interval, ED erectile dysfunction, IPSS International Prostate Symptom Score, OR odds ratio, NE not estimable

OR 95% CI

N

Improved

OR 95% CI

N

Maintained

OR 95% CI

N

Impaired

≥8

<8

< 40 g

≥ 40 g

ED medication
use at baseline ED
medication use at
baseline

IPSS score

Prostate size

BPH medication use at BPH composite measure
baseline

ED -elated factors

BPH-related factors

Sexual bother 12 months post-surgery (n = 329)

All participants n (%)

Table 3 (continued)

16

34

157

Yes

Yang et al. BMC Urol
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urinary incontinence owing to chronic subclinical urinary retention, which may also be relieved by RP.
An additional unexpected observation was our finding
that a small proportion of men who underwent RP experienced improvements beyond baseline in sexual outcomes, particularly long-term sexual bother, independent
of ED therapy. Although resolution of neuropraxia might
explain recovery in these outcomes to baseline levels, we
believe it is unlikely to explain improvements beyond
baseline. Another possible explanation is improved communication surrounding sexual function. Prostate cancer treatment and its known sexual side effects may be
a launching point for men to have an open conversation
with their providers and partners about their sexual function. Previous studies have demonstrated that spousal
communication is a key factor in healthy sexual function recovery after prostate cancer treatment [26]. For
many men, prostate cancer treatment discussions may
prompt discussions regarding sexual function that have
not been addressed in the past. The mechanisms through
which open communication may improve post-RP sexual
outcomes might be similar to those in studies of premenopausal women with dyspareunia, which found that
open communication between partners was critical for
improving sexual function and distress [27].
Another possible explanation for improvement in sexual bother could be relief of sexual bother related to voiding dysfunction post-RP. This hypothesis is supported by
growing evidence that BPH and ED may be caused by
common biologic mechanisms [28]. As such, improvements in BPH-related symptoms from RP may also result
in improvements in sexual outcomes. Alternatively, certain BPH-related medications are known to be associated
with decreased sexual function [29]. Therefore, discontinuation of these drugs may contribute to improvement
following RP, as was observed for men taking α-blockers
pre-RP in our sample. In support of both of these mechanisms, our data demonstrated a higher odds of improved
sexual bother associated with the BPH composite index.
Finally, it is also possible that RP may relieve sexual pain
in men with pre-surgical chronic prostatitis/chronic
pelvic pain syndrome, thereby contributing to improvements in sexual bother. Although each of these explanations is speculative, we believe they warrant further
study for their possible, eventual guidance for prostate
cancer therapeutic decision-making and overall patient
counseling.
Strengths of this study include its prospective design,
large sample size, frequent follow-up of participants
over the one-year study period, and use of validated
outcome measures designed specifically for prostate
cancer survivors. Additionally, use of the EPIC-50

Page 12 of 14

rather than the shorter EPIC-26 allowed us to gain a
more comprehensive understanding of both urinary
and sexual function and bother; and our unique statistical analysis allowed us to explore the full range of outcome trajectories rather than just mean outcome levels.
However, it is also important to note the limitations of
this analysis. Specifically, information on co-existing
urological conditions was not collected systematically
on all participants, but was only available from participants ‘ medical records, which may not have had complete information on these conditions. Additionally,
data were not collected between 5 weeks and 6 months
(e.g., 3 months) to allow us to identify when some outcomes returned to baseline levels.

Conclusions
We observed improvements in urinary and sexual outcomes among non-trivial proportions of men who
underwent RP. Although reasons for improvement in
urinary function (continence) and sexual bother are
unclear, improvement in voiding dysfunction-related
bother likely relates to relief of BPH symptoms by RP, as
prostatectomy is a known, effective therapy for severe
BPH. Therefore, our findings provide additional support for considering baseline BPH symptoms when
selecting the best therapy for early-stage prostate
cancer.
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